Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Norda ASA

Market Cap 513M 54.08M 46.7M 43.04M 40.29M 75.5M 5.14B 76.67M 508M 198M 2.5B 203M 199M 8.66B P/E Ratio 2023 *
-
P/E Ratio 2024 3.26x
Enterprise Value 264M 27.86M 24.06M 22.17M 20.75M 38.89M 2.65B 39.49M 262M 102M 1.29B 105M 102M 4.46B EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day+1.53%
1 month+1.53%
3 months+1.53%
6 months+5.11%
Current year-13.60%
1 month 86.4
Extreme 86.4
86.4
Current year 81
Extreme 81
86.4
1 year 80.1
Extreme 80.1
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 2013-04-07
Director TitleAgeSince
Chairman 54 2014-01-30
Director/Board Member 68 2013-06-19
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.53%-.--%+8.00%+110.73% 46.72M
-0.35%+0.97%-13.80%-13.25% 43.03B
+3.11%+3.11%+279.08%+501.52% 32.71B
+0.22%-1.08%+15.66%-15.65% 30.29B
+1.62%-2.08%-1.91%+24.64% 29.4B
+4.09%+0.93%+12.97%+20.22% 25.08B
-1.63%+2.88%+56.69%+113.41% 13.35B
+1.14%+3.62% - - 13.54B
-0.40%-1.29%+6.23%+7.63% 12.97B
-0.74%-1.62%+105.89%+74.92% 12.11B
Average +0.86%+1.46%+52.09%+91.57% 21.25B
Weighted average by Cap. +1.05%+1.48%+57.29%+96.08%

Financials

2023 2024
Net sales 86.92M 9.16M 7.91M 7.29M 6.82M 12.79M 871M 12.99M 86.08M 33.56M 424M 34.38M 33.64M 1.47B 372M 39.18M 33.84M 31.19M 29.19M 54.71M 3.72B 55.55M 368M 144M 1.81B 147M 144M 6.28B
Net income 31.17M 3.28M 2.84M 2.61M 2.45M 4.59M 312M 4.66M 30.87M 12.04M 152M 12.33M 12.07M 526M 126M 13.27M 11.46M 10.56M 9.89M 18.53M 1.26B 18.82M 125M 48.63M 614M 49.81M 48.75M 2.13B
Net Debt -311M -32.8M -28.33M -26.1M -24.43M -45.79M -3.12B -46.5M -308M -120M -1.52B -123M -120M -5.25B -249M -26.22M -22.65M -20.87M -19.53M -36.61M -2.49B -37.17M -246M -96.07M -1.21B -98.4M -96.31M -4.2B
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
  1. Stock Market
  2. Stocks
  3. NORD Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!